SELLAS Life Sciences (SLS) Asset Writedowns and Impairment (2015 - 2017)
SELLAS Life Sciences (SLS) posted quarterly Asset Writedowns and Impairment of -$3.6 million for Q4 2017, down 200.0% quarter-over-quarter from $3.6 million in Q3 2017.
Powered by 
Analysis
SELLAS Life Sciences (SLS) Asset Writedowns and Impairment (2015 - 2017) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Asset Writedowns and Impairment for 2 consecutive years, with -$3.6 million the latest figure, recorded in Q4 2017.
- In Q4 2017, Asset Writedowns and Impairment changed N/A year-over-year to -$3.6 million; the TTM figure through Sep 2017 stood at $3.6 million (down 55.84% YoY), while the FY2021 annual figure was $5.7 million, changed N/A from the prior year.
- Asset Writedowns and Impairment eased to -$3.6 million in Q4 2017 per SLS's latest filing, from $3.6 million in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $8.1 million in Q3 2015 and bottomed at -$3.6 million in Q4 2017.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn |
| 10 | SELLAS Life Sciences | 2.65 Bn | 2.65 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2017 | -3.56 Mn |
| Sep 30, 2017 | 3.56 Mn |
| Sep 30, 2015 | 8.07 Mn |